In the Psoriatic Arthritis Drug Market, Abbott/Eisai's Humira Will Displace

In the Psoriatic Arthritis Drug Market, Abbott/Eisai's Humira Will Displace
The upcoming Pharmacor advisory service entitled Psoriatic Arthritis, which will be published soon, finds that the TNF-alpha inhibitor etanercept (Amgen/Pfizer/Takeda's Enbrel) was the 2011 market leader, leading by a small margin over adalimumab …

Full News here – Read more on MarketWatch (press release)

Leave a Reply